Marcelo Cerullo1, Faiz Gani1, Sophia Y Chen1, Joseph K Canner1, Timothy M Pawlik2. 1. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. Department of Surgery, The Urban Meyer III and Shelley Meyer Chair for Cancer Research, The Ohio State University Wexner Medical Center, 395 W. 12th Avenue, Suite 670, Columbus, OH, 43210, USA. tim.pawlik@osumc.edu.
Abstract
BACKGROUND: Pancreatic cancer has higher concentrations of angiotensin II compared with other cancers. This study sought to assess the effect of angiotensin II receptor blockers (ARBs) on survival of patients undergoing resection using a large, nationally representative dataset. METHODS: Patients undergoing pancreatic cancer resection were identified in the Truven Health MarketScan database. Multivariable Cox proportional hazards regression was used to assess the effect of ARB use on overall survival. RESULTS: A total of 4299 patients were identified, among whom 479 (11.1%) filled a prescription for an ARB. Mean patient age was 54.5 years (SD = 8.6 years); 2187 (51.1%) were female. Exactly 49.4% (n = 2125) of patients had a Charlson comorbidity index >2 at the time of surgery (n = 2125, 49.4%) and 59.6% (n = 2563) underwent a pancreaticoduodenectomy. Kaplan-Meier estimates of survival at 1, 2, and 4 years were 62.8% (95% CI: 61.3-64.2%), 38.2% (95% CI: 36.6-39.8%), and 19.0% (95% CI: 17.1-21.0%), respectively. On multivariable analysis, ARB use was associated with a 24% decreased risk of death over the 5-year period in which patients were under observation (HR = 0.76, 95% CI: 0.67-0.87, p < 0.001). CONCLUSIONS: ARB use was associated with improved survival in patients undergoing resection of pancreatic cancer. Further research is required into the differential effect of ARBs in the treatment of pancreatic cancer.
BACKGROUND:Pancreatic cancer has higher concentrations of angiotensin II compared with other cancers. This study sought to assess the effect of angiotensin II receptor blockers (ARBs) on survival of patients undergoing resection using a large, nationally representative dataset. METHODS:Patients undergoing pancreatic cancer resection were identified in the Truven Health MarketScan database. Multivariable Cox proportional hazards regression was used to assess the effect of ARB use on overall survival. RESULTS: A total of 4299 patients were identified, among whom 479 (11.1%) filled a prescription for an ARB. Mean patient age was 54.5 years (SD = 8.6 years); 2187 (51.1%) were female. Exactly 49.4% (n = 2125) of patients had a Charlson comorbidity index >2 at the time of surgery (n = 2125, 49.4%) and 59.6% (n = 2563) underwent a pancreaticoduodenectomy. Kaplan-Meier estimates of survival at 1, 2, and 4 years were 62.8% (95% CI: 61.3-64.2%), 38.2% (95% CI: 36.6-39.8%), and 19.0% (95% CI: 17.1-21.0%), respectively. On multivariable analysis, ARB use was associated with a 24% decreased risk of death over the 5-year period in which patients were under observation (HR = 0.76, 95% CI: 0.67-0.87, p < 0.001). CONCLUSIONS: ARB use was associated with improved survival in patients undergoing resection of pancreatic cancer. Further research is required into the differential effect of ARBs in the treatment of pancreatic cancer.
Authors: Skye C Mayo; Hari Nathan; John L Cameron; Kelly Olino; Barish H Edil; Joseph M Herman; Kenzo Hirose; Richard D Schulick; Michael A Choti; Christopher L Wolfgang; Timothy M Pawlik Journal: Cancer Date: 2011-09-20 Impact factor: 6.860
Authors: Benjamin Diop-Frimpong; Vikash P Chauhan; Stephen Krane; Yves Boucher; Rakesh K Jain Journal: Proc Natl Acad Sci U S A Date: 2011-01-31 Impact factor: 11.205
Authors: Y Nakai; H Isayama; H Ijichi; T Sasaki; N Sasahira; K Hirano; H Kogure; K Kawakubo; H Yagioka; Y Yashima; S Mizuno; K Yamamoto; T Arizumi; O Togawa; S Matsubara; T Tsujino; K Tateishi; M Tada; M Omata; K Koike Journal: Br J Cancer Date: 2010-10-26 Impact factor: 7.640
Authors: Vikash P Chauhan; John D Martin; Hao Liu; Delphine A Lacorre; Saloni R Jain; Sergey V Kozin; Triantafyllos Stylianopoulos; Ahmed S Mousa; Xiaoxing Han; Pichet Adstamongkonkul; Zoran Popović; Peigen Huang; Moungi G Bawendi; Yves Boucher; Rakesh K Jain Journal: Nat Commun Date: 2013 Impact factor: 14.919
Authors: Kurinchi Selvan Gurusamy; Deniece Riviere; C J H van Laarhoven; Marc Besselink; Mohammed Abu-Hilal; Brian R Davidson; Steve Morris Journal: PLoS One Date: 2017-12-22 Impact factor: 3.240
Authors: Raquel Yokoda; Bolni M Nagalo; Brent Vernon; Rahmi Oklu; Hassan Albadawi; Thomas T DeLeon; Yumei Zhou; Jan B Egan; Dan G Duda; Mitesh J Borad Journal: Oncolytic Virother Date: 2017-11-08
Authors: Scott W Keith; Vittorio Maio; Hwyda A Arafat; Matthew Alcusky; Thomas Karagiannis; Carol Rabinowitz; Harish Lavu; Daniel Z Louis Journal: BMC Cancer Date: 2022-02-07 Impact factor: 4.430